33 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Miragen Therapeutics, Inc. MGEN shares moved upwards by 17.6% to $1.07 during Monday's pre-market session. The most recent rating by H.C. Wainwright, on August 19, is at Buy, with a price target of $3.00.
• Moleculin Biotech, Inc. MBRX stock increased by 13.2% to $1.20. The market cap seems to be at $40.3 million.
• Co-Diagnostics, Inc. CODX shares increased by 10.6% to $1.25. The market cap seems to be at $35.7 million.
• TrovaGene, Inc. TROV shares moved upwards by 10.1% to $2.30.
• Solid Biosciences, Inc. SLDB shares rose 9.7% to $9.66. The market cap seems to be at $321.5 million. According to the most recent rating by SVB Leerink, on August 19, the current rating is at Outperform.
• Amneal Pharmaceuticals, Inc. AMRX stock rose 8.7% to $2.63. The market cap seems to be at $4.8 billion. The most recent rating by BMO Capital, on August 06, is at Market Perform, with a price target of $5.00.
• Check-Cap, Inc. CHEK shares surged 8.2% to $2.10. The market cap seems to be at $32.7 million.
• Genfit, Inc. GNFT shares rose 7.5% to $16.97. The market cap stands at $638.7 million.
• Pluristem Therapeutics, Inc. PSTI stock surged 6.9% to $3.87. The market cap seems to be at $134.3 million.
• Jaguar Health, Inc. JAGX shares surged 6.3% to $1.18.
• HEXO, Inc. HEXO shares rose 5.7% to $4.70. The market cap seems to be at $1.0 billion. According to the most recent rating by Oppenheimer, on June 25, the current rating is at Perform.
• OptiNose, Inc. OPTN stock moved upwards by 4.9% to $6.66. The market cap stands at $738.5 million. The most recent rating by BMO Capital, on August 13, is at Outperform, with a price target of $24.00.
• InMode, Inc. INMD stock increased by 4.5% to $20.80.
• Sesen Bio, Inc. SESN stock moved upwards by 4.5% to $1.17. The most recent rating by H.C. Wainwright, on June 11, is at Buy, with a price target of $3.00.
• Geron, Inc. GERN stock moved upwards by 3.5% to $1.46. The market value of their outstanding shares is at $391.6 million. The most recent rating by Cantor Fitzgerald, on August 15, is at Overweight, with a price target of $4.00.
• Aurora Cannabis, Inc. ACB shares increased by 3.5% to $6.20. The market value of their outstanding shares is at $6.4 billion.
• Novavax, Inc. NVAX stock surged 3.3% to $8.10.
• Obalon Therapeutics, Inc. OBLN shares increased by 3.3% to $2.50.
• Marker Therapeutics, Inc. MRKR shares moved upwards by 3.3% to $5.70. The market cap seems to be at $120.3 million.
• Aphria, Inc. APHA stock rose 2.8% to $6.34. The market value of their outstanding shares is at $1.3 billion. According to the most recent rating by CIBC, on July 26, the current rating is at Underperformer.
• Arrowhead Pharmaceuticals, Inc. ARWR shares moved upwards by 2.6% to $32.00. The market cap stands at $669.2 million. The most recent rating by B. Riley, on August 19, is at Buy, with a price target of $46.00.
• Tandem Diabetes Care, Inc. TNDM shares surged 2.5% to $60.25. The market cap stands at $2.1 billion.
• aTyr Pharma, Inc. LIFE shares surged 2.3% to $3.07.
• MorphoSys, Inc. MOR stock surged 2.2% to $30.70.
• Canopy Growth, Inc. CGC shares surged 2.1% to $28.70. The most recent rating by Ladenburg Thalmann, on July 17, is at Buy, with a price target of $50.00.

Losers

• Viveve Medical, Inc. VIVE shares fell 18.7% to $0.11 during Monday's pre-market session. According to the most recent rating by Ladenburg Thalmann, on July 24, the current rating is at Neutral.
• Plus Therapeutics, Inc. PSTV stock decreased by 10.0% to $13.00. The market cap seems to be at $226.6 million.
• Vanda Pharmaceuticals, Inc. VNDA stock declined 8.8% to $13.85. The most recent rating by Citi, on August 01, is at Buy, with a price target of $19.00.
• Mustang Bio, Inc. MBIO stock declined 8.7% to $3.55. The most recent rating by H.C. Wainwright, on August 13, is at Buy, with a price target of $7.00.
• Kitov Pharma, Inc. KTOV shares plummeted 4.6% to $0.72. The market cap seems to be at $28.5 million.
• SELLAS Life Sciences, Inc. SLS shares declined 4.3% to $0.15. The market cap stands at $27.0 million.
• Myriad Genetics, Inc. MYGN stock fell 2.3% to $24.77. The market cap stands at $1.3 billion. The most recent rating by Piper Jaffray, on August 14, is at Equal-Weight, with a price target of $40.00.
• Acasti Pharma, Inc. ACST stock plummeted 2.1% to $1.87. The most recent rating by Oppenheimer, on July 18, is at Outperform, with a price target of $7.00.